Anagenics finds a low-cash route back into skincare with Bio-First

Bio-First acquisition priced at $50,000

Anagenics Limited (ASX:AN1) is buying natural skincare brand Bio-First for $50,000, but no cash will change hands. The consideration will be satisfied through the issue of 8,333,333 Anagenics shares at $0.006 each, with completion expected once those shares are issued during November.

The transaction gives Anagenics the Bio-First brand intellectual property, formulations, customer database and digital assets, plus a pipeline of more than 10 developed product concepts. Bio-First has recorded more than 17,000 purchasers, a customer email database exceeding 25,000 contacts and more than 1,700 reviews, according to the announcement.

BLC channels set the relaunch route

Anagenics intends to relaunch Bio-First through BLC Cosmetics’ existing ecommerce, warehousing and professional beauty distribution infrastructure. The initial plan is to reactivate existing customers, relaunch core products and expand access through BLC’s network of clinics, salons and spas.

The acquisition follows Anagenics’ $2.5 million IP sale, which delivered an upfront payment and retained an earn-out linked to future product sales. Anagenics said that transaction strengthened its balance sheet and underpinned annual royalties, creating the backdrop for a strategy focused on owned brands and intellectual property.

Relaunch costs and dilution remain open questions

Chair Sandy Beard described Bio-First as a complementary brand with proven formulations and a substantial customer base, saying the company sees an opportunity to relaunch it through existing channels. The announcement does not provide revenue, profitability or relaunch cost forecasts for Bio-First, so the eventual return on the investment cannot yet be assessed from the disclosed figures.

The share-funded structure preserves Anagenics’ cash for the relaunch, but it also means existing shareholders will receive the commercial outcome alongside the dilution from the new shares. Anagenics is reviewing its brand portfolio and expects to provide more detail on its strategy to improve scale and profitability, as well as potential complementary investments, in the new year.